1
|
Ghamari N, Zarei O, Arias-Montaño JA, Reiner D, Dastmalchi S, Stark H, Hamzeh-Mivehroud M. Histamine H 3 receptor antagonists/inverse agonists: Where do they go? Pharmacol Ther 2019; 200:69-84. [PMID: 31028835 DOI: 10.1016/j.pharmthera.2019.04.007] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2018] [Accepted: 04/19/2019] [Indexed: 12/16/2022]
Abstract
Since the discovery of the histamine H3 receptor in 1983, tremendous advances in the pharmacological aspects of H3 receptor antagonists/inverse agonists have been accomplished in preclinical studies. At present, there are several drug candidates that reached clinical trial studies for various indications. However, entrance of these candidates to the pharmaceutical market is not free from challenges, and a variety of difficulties is engaged with their developmental process. In this review, the potential role of H3 receptors in the pathophysiology of various central nervous system, metabolic and allergic diseases is discussed. Thereafter, the current status for H3 receptor antagonists/inverse agonists in ongoing clinical trial studies is reviewed and obstacles in developing these agents are emphasized.
Collapse
Affiliation(s)
- Nakisa Ghamari
- Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Omid Zarei
- Cellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran; Neurosciences Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran
| | - José-Antonio Arias-Montaño
- Departamento de Fisiología, Biofísica y Neurociencias, Centro de Investigación y de Estudios Avanzados del IPN, Av. Instituto Politécnico Nacional 2508, Zacatenco, 07360 Ciudad de México, México
| | - David Reiner
- Heinrich Heine University Düsseldorf, Institute of Pharmaceutical and Medicinal Chemistry, Universitaetsstr. 1, 40225 Duesseldorf, Germany
| | - Siavoush Dastmalchi
- Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Holger Stark
- Heinrich Heine University Düsseldorf, Institute of Pharmaceutical and Medicinal Chemistry, Universitaetsstr. 1, 40225 Duesseldorf, Germany.
| | - Maryam Hamzeh-Mivehroud
- Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
| |
Collapse
|
2
|
|
3
|
Akhtar W, Shaquiquzzaman M, Akhter M, Verma G, Khan MF, Alam MM. The therapeutic journey of pyridazinone. Eur J Med Chem 2016; 123:256-281. [DOI: 10.1016/j.ejmech.2016.07.061] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2016] [Revised: 07/20/2016] [Accepted: 07/24/2016] [Indexed: 11/17/2022]
|
4
|
Hudkins RL, Becknell NC, Lyons JA, Aimone LD, Olsen M, Haltiwanger RC, Mathiasen JR, Raddatz R, Gruner JA. 3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity. Eur J Med Chem 2015; 95:349-56. [DOI: 10.1016/j.ejmech.2015.03.054] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2014] [Revised: 03/21/2015] [Accepted: 03/23/2015] [Indexed: 12/25/2022]
|
5
|
Hudkins RL, Josef KA, Becknell NC, Aimone LD, Lyons JA, Mathiasen JR, Gruner JA, Raddatz R. Discovery of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a): histamine H(3) receptor inverse agonist demonstrating potent cognitive enhancing and wake promoting activity. Bioorg Med Chem Lett 2014; 24:1303-6. [PMID: 24513042 DOI: 10.1016/j.bmcl.2014.01.061] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2013] [Revised: 01/16/2014] [Accepted: 01/21/2014] [Indexed: 02/01/2023]
Abstract
A series of fused cyclopropyl-4,5-dihydropyridazin-3-one (3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one) phenoxypiperidine analogs was designed and synthesized, leading to the identification of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a) as a second-generation pyridazin-3-one H3R antagonist. Compound R,S-4a was a potent H3R functional antagonist in vivo in the rat dipsogenia model, demonstrated potent wake activity in the rat EEG/EMG model, and enhanced short-term memory in the rat social recognition memory model at doses as low as 0.03-0.3 mg/kg po.
Collapse
Affiliation(s)
- Robert L Hudkins
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA.
| | - Kurt A Josef
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Nadine C Becknell
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Lisa D Aimone
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Jacquelyn A Lyons
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Joanne R Mathiasen
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - John A Gruner
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Rita Raddatz
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| |
Collapse
|
6
|
Liang L, Yang G, Xu F, Niu Y, Sun Q, Xu P. Copper-Catalyzed Aerobic Dehydrogenation of C-C to C=C Bonds in the Synthesis of Pyridazinones. European J Org Chem 2013. [DOI: 10.1002/ejoc.201300640] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
7
|
Liang L, Yang G, Wang W, Xu F, Niu Y, Sun Q, Xu P. A Copper-Catalyzed Aerobic Cascade Dehydrogenative- Dehalogenative Reaction. Adv Synth Catal 2013. [DOI: 10.1002/adsc.201300026] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
8
|
Josef KA, Aimone LD, Lyons J, Raddatz R, Hudkins RL. Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H3 receptor inverse agonists. Bioorg Med Chem Lett 2012; 22:4198-202. [DOI: 10.1016/j.bmcl.2012.04.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2011] [Revised: 03/23/2012] [Accepted: 04/02/2012] [Indexed: 10/28/2022]
|
9
|
Synthesis and evaluation of 4- and 5-pyridazin-3-one phenoxypropylamine analogues as histamine-3 receptor antagonists. Bioorg Med Chem 2012; 20:3880-6. [DOI: 10.1016/j.bmc.2012.04.028] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2011] [Revised: 04/04/2012] [Accepted: 04/10/2012] [Indexed: 12/12/2022]
|
10
|
Zulli AL, Aimone LD, Mathiasen JR, Gruner JA, Raddatz R, Bacon ER, Hudkins RL. Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists. Bioorg Med Chem Lett 2012; 22:2807-10. [DOI: 10.1016/j.bmcl.2012.02.081] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2012] [Revised: 02/22/2012] [Accepted: 02/23/2012] [Indexed: 10/28/2022]
|
11
|
Dandu RR, Lyons JA, Raddatz R, Huang Z, Aimone LD, Hudkins RL. Synthesis and evaluation of a new series of 1′-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4′-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists. Bioorg Med Chem Lett 2012; 22:2151-3. [DOI: 10.1016/j.bmcl.2012.01.139] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2011] [Revised: 01/30/2012] [Accepted: 01/31/2012] [Indexed: 11/24/2022]
|
12
|
Sundar BG, Bailey TR, Dunn D, Hostetler GA, Chatterjee S, Bacon ER, Yue C, Schweizer D, Aimone LD, Gruner JA, Lyons J, Raddatz R, Lesur B. Novel morpholine ketone analogs as potent histamine H3 receptor inverse agonists with wake activity. Bioorg Med Chem Lett 2012; 22:1546-9. [DOI: 10.1016/j.bmcl.2012.01.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2011] [Revised: 01/02/2012] [Accepted: 01/03/2012] [Indexed: 11/28/2022]
|
13
|
Hudkins RL, Zulli AL, Dandu RR, Tao M, Josef KA, Aimone LD, Haltiwanger RC, Huang Z, Lyons JA, Mathiasen JR, Raddatz R, Gruner JA. 4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activity. Bioorg Med Chem Lett 2012; 22:1504-9. [PMID: 22290075 DOI: 10.1016/j.bmcl.2012.01.026] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2011] [Revised: 01/04/2012] [Accepted: 01/09/2012] [Indexed: 11/25/2022]
Abstract
Structure-activity relationships for a series of phenoxypiperidine pyridazin-3-one H(3)R antagonists/inverse agonists are disclosed. The search for compounds with improved hERG and DAT selectivity without the formation of in vivo active metabolites identified 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one 17b. Compound 17b met discovery flow criteria, demonstrated potent H(3)R functional antagonism in vivo in the rat dipsogenia model and potent wake activity in the rat EEG/EMG model at doses as low as 0.1 mg/kg ip.
Collapse
Affiliation(s)
- Robert L Hudkins
- Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Hudkins RL, Aimone LD, Dandu RR, Dunn D, Gruner JA, Huang Z, Josef KA, Lyons JA, Mathiasen JR, Tao M, Zulli AL, Raddatz R. 4,5-Dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists. Bioorg Med Chem Lett 2012; 22:194-8. [DOI: 10.1016/j.bmcl.2011.11.037] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2011] [Revised: 11/08/2011] [Accepted: 11/09/2011] [Indexed: 01/29/2023]
|
15
|
Andrews JR, Filer CN, Maniscalco M, Becknell NC, Hudkins RL. High specific activity tritiation of the pyridazin-3-one histamine H3 receptor inverse agonist CEP-27088. Appl Radiat Isot 2011; 70:512-4. [PMID: 22177523 DOI: 10.1016/j.apradiso.2011.11.061] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2011] [Revised: 11/24/2011] [Accepted: 11/29/2011] [Indexed: 11/24/2022]
Abstract
Methods are presented to tritiate and characterize radioligand (3).
Collapse
|
16
|
Synthesis and evaluation of pyridone-phenoxypropyl-R-2-methylpyrrolidine analogues as histamine H3 receptor antagonists. Bioorg Med Chem Lett 2011; 21:7076-80. [DOI: 10.1016/j.bmcl.2011.09.091] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2011] [Revised: 09/19/2011] [Accepted: 09/21/2011] [Indexed: 11/18/2022]
|
17
|
Becknell NC, Dandu RR, Lyons JA, Aimone LD, Raddatz R, Hudkins RL. Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists. Bioorg Med Chem Lett 2011; 22:186-9. [PMID: 22153342 DOI: 10.1016/j.bmcl.2011.11.038] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2011] [Revised: 11/08/2011] [Accepted: 11/09/2011] [Indexed: 12/31/2022]
Abstract
A novel class of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues were designed and synthesized as H(3)R antagonists. Structure-activity relationship identified sulfone 27 with excellent H(3)R affinities in both humans and rats, and acceptable pharmacokinetic properties. Further, compound 28 achieved single digit nanomolar H(3)R affinities in both species with minimum hERG activity.
Collapse
Affiliation(s)
- Nadine C Becknell
- Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA.
| | | | | | | | | | | |
Collapse
|
18
|
Synthesis and evaluation of pyridazinone–phenethylamine derivatives as selective and orally bioavailable histamine H3 receptor antagonists with robust wake-promoting activity. Bioorg Med Chem Lett 2011; 21:6362-5. [DOI: 10.1016/j.bmcl.2011.08.104] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2011] [Revised: 08/19/2011] [Accepted: 08/25/2011] [Indexed: 11/19/2022]
|